Data for outcomes of acute hospital administration of amiodarone and/or lidocaine in shockable patients presenting with out-of-hospital cardiac arrest  by Huang, Chien-Hua et al.
Contents lists available at ScienceDirect
Data in Brief
Data in Brief 10 (2017) 57–62http://d
2352-34
(http://c
DOI
n Corr
E-mjournal homepage: www.elsevier.com/locate/dibData ArticleData for outcomes of acute hospital
administration of amiodarone and/or lidocaine
in shockable patients presenting
with out-of-hospital cardiac arrest
Chien-Hua Huang, Ping-Hsun Yu, Min-Shan Tsai,
Po-Ya Chuang, Tzung-Dau Wang, Chih-Yen Chiang,
Wei-Tien Chang, Matthew Huei-Ming Ma, Chao-Hsiun Tang,
Wen-Jone Chen n
Department of Emergency Medicine and Department of Internal Medicine (Cardiology), College of Medicine,
National Taiwan University, Taipei, Taiwana r t i c l e i n f o
Article history:
Received 9 November 2016
Received in revised form
17 November 2016
Accepted 23 November 2016
Available online 30 November 2016x.doi.org/10.1016/j.dib.2016.11.085
09/& 2016 The Authors. Published by Else
reativecommons.org/licenses/by/4.0/).
of original article: http://dx.doi.org/10.1016
esponding author.
ail address: wjchen1955@ntu.edu.tw (W.-J.a b s t r a c t
The data presented in this article are related to the research article
entitled “Acute Hospital Administration of Amiodarone and/or
Lidocaine in Shockable Patients Presenting with Out-of-hospital
Cardiac Arrest: A Nationwide Cohort Study” (C.H. Huang, P.H. Yu,
M.S. Tsai et al., 2016) [1]. The data contains the information of co-
morbidities coding from ICD-9 CM codes and speciﬁc difference in
requirement between medical centers and non-medical centers in
resuscitation. Univariate and multivariate logistic regression ana-
lysis for factors related to the outcome of survival to ICU admission
and survival to hospital discharge are included in the data set. The
data also contains bootstrap sensitivity analysis of the logistic
regression model for survival to ICU admission and hospital dis-
charge outcomes in out-of-hospital cardiac arrest. Subgroup ana-
lysis of epinephrine dosage related to outcome of one-year survival
is shown.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
/j.ijcard.2016.11.101
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Table 1
Co-morbidities coding from
Co-morbidities
Diabetes mellitus
Hypertension
Coronary artery disease
Congestive heart failure
Atrial ﬁbrillation
Chronic kidney disease
Malignancy
Chronic obstructive pulmo
Asthmaubject area Biology
ore speciﬁc sub-
ject areaAcute cardiac careype of data Tables
ow data was
acquiredData analysis for national health insurance databaseata format Analyzed
xperimental factors Data are analyzed to ﬁgure out the outcomes related variables
xperimental
featuresRetrospective, observational, and nationwide population-based cohort study of
patients with non-traumatic cardiac arrestata source location A nationwide cohort study in Taiwan
ata accessibility The analyzed data is with this article.Value of the data
 The data provide information the ways of coding co-morbidities and hospital levels in the
resuscitation study. The short term outcomes of survival to hospital admission, intermediate
outcome of survival to hospital discharge are important in cardiac arrest patient.
 The data provides the information so that the effects of speciﬁc intervention can be comprehen-
sively ﬁgured out and compared.
 Subgroup analysis of patients with different dosage of epinephrine used in resuscitation show the
interaction with effects of anti-arrhythmic agents.1. Data
The data contains the information of co-morbidities coding from ICD-9 CM codes and speciﬁc
difference in requirement between medical centers and non-medical centers in resuscitation as
shown in Tables 1 and 2. Univariate and multivariate logistic regression analysis for factors related to
the outcome of survival to ICU admission and survival to hospital discharge are included in the data
set Tables 3a and 3b. The data also contains bootstrap sensitivity analysis of the logistic regression
model for survival to ICU admission and hospital discharge outcomes in out-of-hospital cardiac arrest
as shown in Table 4. Subgroup analysis of epinephrine dosage related to outcome of one-year survival
is shown in Table 5.ICD-9 CM codes.
ICD-9 CM codes
250.*
401.*, 402.*, 403.*, 404.*, 405.*
410.*, 411.*, 412.*, 413.*, 414.*
428.*
427.31
585
140.*172.*, 174.*194*, 200.*208.*
nary disease 491.*, 492.*, 494.*, 496.*
493.*
Table 2
Speciﬁc difference in requirement between medical centers and non-medical centers in resuscitation.
Medical centre Non-medical centre
Chief of emergency department Emergency medicine specialist Any medical specialist
Physician qualiﬁcation 1. 70% of total physicians are ﬁxed in ED
2. More than 50% of total ﬁxed physician are
emergency medicine specialist
1. 30% of total physicians are ﬁxed in ED
2. Any medical specialist
Qualiﬁed advanced cardiac life
support (ACLS) training
More than 75% of total stuff (including physi-
cians and nurses)
More than 50% of total stuff (including
physicians and nurses)
Management for acute coronary
syndrome
Cardiologist and cardiovascular surgeon con-
sultation at any time
Cardiologist consultation at any time
Perform percutaneous coronary
intervention
1. Always available at any time 1. Not always available
2. Door-to-balloon time o90 min in 75% of
total STEMI patients
2. Transfer the patient if PCI is not
available
Table 3a
Univariate and multivariate logistic regression analysis for factors related to the outcome of survival to ICU admission.
Univariate Multivariate
OR (95% CI) P value OR (95% CI) P value
Age (pear year) 0.99(0.990.99) o0.0001 0.99 (0.980.99) o0.0001
Male 0.92(0.870.98) 0.0141 0.91(0.850.98) 0.01
Medication use
Both 2.82(2.523.17) o0.0001 4.05(3.564.61) o0.0001
Amiodarone 2.04(1.902.18) o0.0001 2.23(2.072.41) o0.0001
Lidocaine 1.87(1.622.16) o0.0001 2.32(1.992.71) o0.0001
Neither 1 1
Urbanization level
1 1.35(1.241.47) 1.23(1.121.36) o0.0001
2 1.41(1.301.52) 1.26(1.161.37) o0.0001
3 1.22(1.101.37) 1.36(1.211.53) o0.0001
4 1 1
CCI 0.98(0.970.99) o0.0001
Pre-existing medical diseasea
DM 1.06(0.99561.14) 0.06
Hypertension 0.93(0.870.98) 0.01
CAD 0.88(0.820.95) 0.0007 0.89(0.820.97) 0.005
HF 0.94(0.861.03) 0.18
Af 1.16(0.991.35) 0.06 1.20(1.011.41) 0.03
CKD 1.16(1.051.28) 0.0024
Malignancy 0.93(0.831.03) 0.17 0.88(0.780.98) 0.02
COPD 0.80(0.730.88) o0.0001
Asthma 0.85(0.750.97) 0.01
Year of events
2004 1 1
2005 1.17(1.031.33) 0.01 1.19(1.041.35) 0.01
2006 1.54(1.371.74) o0.0001 1.50(1.321.70) o0.0001
2007 1.54(1.361.74) o0.0001 1.48(1.301.69) o0.0001
2008 1.82(1.612.05) o0.0001 1.75(1.541.99) o0.0001
2009 1.78(1.572.01) o0.0001 1.81(1.592.06) o0.0001
2010 1.82(1.612.07) o0.0001 1.78(1.562.03) o0.0001
2011 1.73(1.521.96) o0.0001 1.72(1.501.97) o0.0001
Epinephrine dose (per mg) 0.90(0.890.90) o0.0001 0.87(0.870.88) o0.0001
Vasopressin use 2.14(0.974.48) 0.03 2.86(1.356.06) 0.006
Resuscitation in medical centre 1.70(1.581.82) o0.0001 1.60(1.471.74) o0.0001
Regression to age, gender, underlying diseases, Charlson comorbidity index, epinephrine dose, vasopressin use, hospital level,
urbanization level, year of event.
OD: odds ratio, CI: conﬁdence interval.
a CCI: Charlson comorbidity index; DM: diabetes mellitus; CAD: coronary artery disease; HF: heart failure; Af: atrial
ﬁbrillation; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease.
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Table 3b
Univariate and multivariate analysis for factors related to the outcome of survival to hospital discharge.
Univariate Multivariate
OR (95% CI) P value OR (95% CI) P value
Age, pear year 0.98(0.980.98) o0.0001 0.99
(0.980.99)
o0.0001
Male 1.16(1.031.30) 0.01
Medication
Both 4.46(3.765.28) o0.0001 4.26
(3.365.41)
o0.0001
Amiodarone 3.08(2.743.45) o0.0001 2.79
(2.403.24)
o0.0001
Lidocaine 2.66(2.113.35) o0.0001 2.51
(1.883.36)
o0.0001
Neither 1 1
Urbanization Level
1 1.50 (1.291.73) o0.0001
2 1.35 (1.181.55) o0.0001
3 1.13 (0.931.38) 0.23
4 1
CCI 0.88(0.860.90) o0.0001 0.95
(0.920.99)
0.005
Pre-existing medical diseasea
DM 0.77
(0.680.88)
o0.0001
Hypertension 0.80
(0.710.89)
o0.0001
CAD 0.81
(0.710.93)
0.0026
heart failure 0.86
(0.731.00)
0.052
Af 0.90
(0.661.21)
0.50
CKD 1.03(0.861.23) 0.74 1.46
(1.161.84)
0.001
Malignancy 0.63
(0.500.79)
o0.0001
CPOD 0.58
(0.490.69)
o0.0001
Asthma 0.76
(0.590.97)
0.03 1.45
(1.121.90)
0.006
Year of events
2004 1
2005 1.13(0.901.42) 0.29
2006 1.44(1.161.79) 0.0011
2007 1.53(1.231.91) 0.0002
2008 1.78(1.442.21) o0.0001
2009 1.85(1.492.30) o0.0001
2010 1.86(1.492.32) o0.0001
2011 1.73(1.382.17) o0.0001
Epinephrine dose (per mg) 0.79
(0.780.80)
o0.0001 0.80
(0.790.81)
o0.0001
Vasopressin 1.04(0.124.07) 0.72
Resuscitation in medical
centre
1.91(1.702.14) o0.0001 1.38
(1.191.61)
o0.0001
Coronary angiography 66.71
(56.9078.25)
o0.0001 32.86
(27.1139.83)
o0.0001
Hypothermia 11.28
(6.9218.14)
o0.0001
Regression to age, gender, underlying diseases, Charlson comorbidity index, epinephrine dose, vasopressin use, hospital level,
urbanization level, year of event, coronary angiography.
OD: odds ratio, CI: conﬁdence interval.
a CCI: Charlson comorbidity index; DM: diabetes mellitus; CAD: coronary artery disease; HF: heart failure; Af: atrial
ﬁbrillation; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease.
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Table 5
Subgroup analysis of epinephrine dosage related to outcome of one-year survivaln.
Epinephrine dosage Both Amiodarone Lidocaine Neither
o¼5 mg 2.60(1.723.93) 2.36(1.882.96) 2.06(1.343.16) Reference
P value o0.0001 o0.0001 0.0009
6–10 mg 2.47(1.543.98) 2.37(1.793.14) 1.83(1.013.32) Reference
P value 0.0002 o0.0001 0.047
11–15 mg 2.51(1.454.33) 1.18(0.781.80) 1.31(0.563.05) Reference
P value 0.001 0.43 0.54
415 mg 1.46(0.852.51) 1.33(0.882.02) 1.18(0.462.98) Reference
P value 0.17 0.17 0.73
P value for interaction o0.0001.
Table 4
Bootstrap sensitivity analysis of the logistic regression model for survival to ICU admission and hospital discharge outcomes in
out-of-hospital cardiac arrest.
Survival to ICU admission Survival to discharge
Adjusted OR (95%
CI)
P value Adjusted OR (95%
CI)
P value
Primary analysis
Both 4.05(4.044.07) o0.0001 4.17(4.144.20) o0.0001
Amiodarone 2.23(2.232.24) o0.0001 2.72(2.702.73) o0.0001
Lidocaine 2.33(2.322.34) o0.0001 2.51(2.482.53) o0.0001
Neither Reference Reference
Excluding patients with pre-existing malignancy
Both 4.15(4.134.17) o0.0001 4.14(4.114.17) o0.0001
Amiodarone 2.32(2.312.32) o0.0001 2.71(2.702.73) o0.0001
Lidocaine 2.51(2.502.52) o0.0001 2.63(2.602.65) o0.0001
Neither Reference Reference
Excluding patients receiving no epinephrine
Both 3.97(3.953.99) o0.0001 4.43(4.394.46) o0.0001
Amiodarone 2.16(2.162.17) o0.0001 2.81(2.802.83) o0.0001
Lidocaine 2.19(2.182.20) o0.0001 2.41(2.392.44) o0.0001
Neither Reference Reference
Excluding patients receiving epinephrine 0 or 1 mg
Both 3.86(3.853.88) o0.0001 4.38(4.344.11) o0.0001
Amiodarone 2.12(2.112.12) o0.0001 2.86(2.842.87) o0.0001
Lidocaine 2.11(2.102.12) o0.0001 2.46(2.432.49) o0.0001
Neither Reference Reference
OR: odds ratio, CI: conﬁdence interval.
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Medical records/reports accruing between years 2004 and 2011 were retrieved from the Taiwan
National Health Insurance Research Database (NHIRD) for review. This repository releases anonymous
secondary data for research purposes and houses all claims data from the National Health Insurance
(NHI) program in Taiwan. Launched in 1995, the NHI provides coverage for 499% of the entire Tai-
wanese population of 23.74 million [2]. The database details all patient demographics and orders for
medical care. Taiwan's NHI Bureau is responsible for comprehensive review of medical records and
examination reports [3]. Disease diagnoses are coded according to the International Classiﬁcation of
Disease, Ninth Revision, Clinical Modiﬁcation (ICD-9-CM). The study protocol was approved by the
National Taiwan University Hospital Research Ethics Committee.
C.-H. Huang et al. / Data in Brief 10 (2017) 57–62623. Study design
This retrospective, observational, and nationwide population-based cohort study of patients with
non-traumatic cardiac arrest was designed to investigate the impact of amiodarone and lidocaine
usage on survival outcomes. Subjects were selected entirely from the NHIRD, all undergoing DC shock
and cardiopulmonary resuscitation during short emergency room stay between January, 2004 and
December, 2011. Grounds for exclusion were stipulated as follows: 1) age o18 years, 2) trauma-
related event, 3) emergency room stay 46 h, or 4) non-level one triage. Patients were categorized
and triaged into level-one if vital signs were extremely unstable and needed immediate resuscitation
when presented to emergency department. Any known recipients of lidocaine or amiodarone (oral or
intravenous) within 1 year previously were also excluded to minimize therapeutic interference.
Patients were followed from cardiac arrest index date to 1-year survival status or death. Analysis was
based on data from emergency rooms and hospitalization and not from ambulance or from resus-
citation on the scene in the study [1].Acknowledgments
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